ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Clinical Trial Design

IASLC Studying Impact of COVID-19 on International Lung Cancer Clinical Trial Enrollment, Mitigation Strategies

Joy Curzio
on: May 06, 2021In: Clinical Trial Design
IASLC Studying Impact of COVID-19 on International Lung Cancer Clinical Trial Enrollment, Mitigation
            Strategies

Although clinical trials are vitally important to researchers working to improve therapies for lung cancer, clinical trials also provide what could be lifesaving treatments to those patients on trials. When […] Read more


Cancer Clinical Trial Compensation: Undue or Long Overdue?

Jennifer Byrne
on: March 24, 2021In: Clinical Trial Design
Cancer Clinical Trial Compensation: Undue or Long Overdue?

When compensating participants in clinical trials, the objective is to show appreciation and consideration for a patient’s time and expenses without exerting undue influence. The Office for Human Research Protections […] Read more

Revised U.S. Food and Drug Administration Trial Eligibility Guidance: A Major Step Toward Transforming Lung Cancer Clinical Trials

David E. Gerber, MD
+more
on: January 21, 2021In: Clinical Trial Design
Revised U.S. Food and Drug Administration Trial Eligibility Guidance: A Major Step Toward Transforming
            Lung Cancer Clinical Trials

By now, investigators, sponsors, clinicians, and patients are widely aware of the crisis facing cancer clinical trials. With scientific discoveries occurring more rapidly than ever, there is a growing need […] Read more

SEARCH ILCN

Archives

PROVIDER RESOURCES

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

INDUSTRY SUPPORTED


COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

INDUSTRY SUPPORTED

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy